-
Product Insights
Leukodystrophies – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukodystrophies - Drugs In Development, 2023’, provides an overview of the Leukodystrophies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukodystrophies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Sensorineural Hearing Loss – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Drugs In Development, 2023’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hearing Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Hearing Disorders - Drugs In Development, 2023’, provides an overview of the Hearing Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Myr-101 in Canavan Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Myr-101 in Canavan DiseaseDrug Details:Myr-101 is under development for the treatment of typical Canavan disease. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MG01-T521 in Allergic Rhinitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MG01-T521 in Allergic Rhinitis Drug Details: MG01-T521 is under development for the treatment of allergic rhinitis,...
-
Product Insights
Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Canavan Disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the build-up of N-acetylaspartic acid (NAA) in the brain. The build-up of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss. The Canavan Disease pipeline...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – rAAV-Olig001-ASPA
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rAAV-Olig001-ASPA Drug Details rAAV-Olig001-ASPAÂ is under development for the treatment of typical Canavan disease. It...